SF IDRC Open Clinical Studies

 

Interested in joining a clinical research study?

The San Francisco Infectious Diseases Research Center (SF IDRC) conducts cutting-edge clinical trials to advance treatments for HIV and other infectious diseases. By participating, you can play a vital role in helping improve care, prevention, and treatment strategies for individuals affected by these conditions.

Click on our open clinical studies below to learn more.

  • Participants typically will receive compensation for their participation, with the amount varying depending on the specific clinical trial.

  • For more information or to inquire about enrollment, please email [email protected] or text/call 415-806-8554.

Studies for People Living with HIV

A5321 – Observational Study for People with New Confirmed or Suspected HIV Infection After Use of Injectable Cabotegravir for HIV PrEP (Group 6)
Basic Eligibility Criteria

Individuals who have used injectable cabotegravir for PrEP within 90 days of a blood sample concerning for possible HIV infection. Excludes those with HIV RNA >1000 copies/mL or who are currently on antiretroviral therapy (ART).

Study Design

This observational study aims to characterize the HIV reservoir, inflammatory consequences, and viral evolution after breakthrough infection, including after ART initiation. Participants will also be referred to the SeroPrep Study.
A5402 – An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV
Basic Eligibility Criteria

Adults aged 18–70 living with HIV, with a confirmed diagnosis of MDD, stable on ART for ≥3 months, undetectable viral load, not currently on antidepressants, and able to take oral medication. Those who can become pregnant must test negative and use contraception.

Study Design

This study compares pramipexole extended release versus escitalopram for treating MDD and MDD with MND in people with HIV, while also examining impacts on daily functioning.
A5422 – Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive Antiretroviral Therapy
Basic Eligibility Criteria

Adults aged 18+ living with HIV-1, on stable ART for ≥2 years, with a CD4+ count ≥200, HIV viral load <50 for the past year, no current Hepatitis B or C infection, and using birth control if applicable.

Study Design

Evaluates the safety and immune effects of an investigational HIV vaccine. Participants receive 10 injections (five per arm) over a year. Random assignment gives a 2-in-3 chance of receiving the vaccine and a 1-in-3 chance of placebo.
A5424 – Menopausal Hormone Therapy for Women Living with HIV (HoT Study)
Basic Eligibility Criteria

Individuals assigned female at birth, ages 40–60, in late perimenopause or early postmenopause, living with HIV, on ART for >1 year, not pregnant, and willing to use contraception and complete a daily diary.

Study Design

This two-group study compares hormone replacement therapy (estradiol gel with or without oral progesterone) to placebo in women with HIV.
Gilead Wonders – Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Basic Eligibility Criteria

Adults aged 18+ with HIV-1 who have maintained HIV RNA <50 copies/mL and have been on Biktarvy (BVY) for ≥24 weeks.

Study Design

Tests the safety and effectiveness of switching from daily Biktarvy to a once-weekly oral treatment with GS-1720 and GS-4182.
Merck 060 – Phase 2 Study of ISL+ULO Once Weekly in Virologically Suppressed Adults With HIV-1
Basic Eligibility Criteria

Adults living with HIV-1, currently taking BIC/FTC/TAF with good viral control for ≥6 months, and no history of treatment failure. Retesting allowed within 45 days if screening values are borderline.

Study Design

Compares once-weekly ISL+ULO treatment to daily BIC/FTC/TAF by evaluating HIV viral control after 24 weeks.

Viral Hepatitis Studies

A5394 – Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV
Basic Eligibility Criteria

Adults aged 18–70, living with HIV and chronic Hepatitis B, with suppressed viral loads, HBsAg positive, on dual ART and HBV therapy for >5 years, CD4 >350, no Hep C, and no recent Hep C treatment.

Study Design

Phase II, double-blind, randomized placebo-controlled trial testing once-weekly oral Selgantolimod for 24 weeks to assess safety and impact on hepatitis B surface antigen.

Looking for a different study?

Click here to explore other clinical studies offered by our Division.